Foundation Medicine has appointed Suzanne Fleming as Vice President, Finance. Prior to joining Foundation Medicine, Fleming served as Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals. Previously, from 2005-2013, Fleming served as Vice President, Finance at AVEO Oncology. From 2003-2005, Fleming worked at Transform Pharmaceuticals, Inc. (acquired by Johnson & Johnson) as Senior Director, Finance. Her early career includes roles at Transkaryotic Therapies, Inc. (Executive Director, Finance), CytoTherapeutics, Inc. (Director, Finance, and Controller), and Oculon Corporation (Controller). From 1986-1987, Fleming served as Manager at KPMG Peat Marwick and from 1983-1986, served as Senior Accountant at Wolf & Company of Massachusetts.
Fleming received her B.S. in Accounting from Stonehill College and is a C.P.A.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient's cancer to help physicians in matching them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.